文献速递妇产影像泌尿生殖US

妇科疾病影像学(14):卵巢透明细胞癌的临床与超声特征

Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-01-01

这项回顾性研究纳入11个超声中心的152例经组织学证实的卵巢纯透明细胞癌患者,分析其临床与超声特征。肿瘤多为单侧、含实性成分的大肿块,60.5%为FIGO I期;起源于子宫内膜异位症的透明细胞癌患者更年轻,且囊液「毛玻璃样回声」更常见。

要点

  • 卵巢纯透明细胞癌多为单侧含实性成分的大肿块,中位最大径117 mm,84.2%为单侧。
  • 23.7%表现为完全实性肿块,38.2%见乳头状突起,其中91.1%乳头状突起有血流信号。
  • 起源于子宫内膜异位症者更年轻(中位47.5岁 vs 55.0岁),囊液毛玻璃样回声更常见(50.0% vs 16.5%)。

核心结论

  • 卵巢纯透明细胞癌通常诊断于早期,典型表现为含实性成分的单侧大肿块;起源于子宫内膜异位症的透明细胞癌患者更年轻,且囊液毛玻璃样回声更常见。

研究设计与样本

  • 回顾性研究,纳入11个超声中心,共152例经组织学证实的卵巢纯透明细胞癌患者;其中105例来自国际卵巢肿瘤分析(IOTA)数据库(1999—2016年,由经验丰富的超声检查者行术前超声),另47例来自参与中心妇科肿瘤科数据库(1999—2016年,有完整术前超声报告);所有肿瘤超声图像按IOTA术语描述。

关键影像表现/征象

  • 全部肿瘤均含实性成分,36/152(23.7%)为完全实性肿块。
  • 病灶中位最大径117 mm(范围25—310 mm),128/152(84.2%)为单侧。
  • 58/152(38.2%)见乳头状突起,其中51/56(91.1%)乳头状突起可见血流信号。
  • 起源于子宫内膜异位症的透明细胞癌中囊液毛玻璃样回声为10/20(50.0%),无此证据者为13/79(16.5%)。

诊断标准与关键数值

  • FIGO I期92/152(60.5%)。
  • 152例患者中位年龄53.5岁(范围28—92岁)。
  • 130/152例有组织学盆腔子宫内膜异位症信息,其中54例(41.5%)存在子宫内膜异位症,24/130(18.6%)判定肿瘤起源于子宫内膜异位症。
  • 有肿瘤起源于子宫内膜异位症证据者中位年龄47.5岁,无此证据者中位年龄55.0岁。

临床应用与阅片要点

  • 阅片时注意含实性成分的单侧大肿块,完全实性肿块占23.7%,乳头状突起占38.2%且多数有血流信号。
  • 对年轻患者伴囊液毛玻璃样回声者,需结合病史考虑透明细胞癌起源于子宫内膜异位症的可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To describe the clinical and ultrasound characteristics of ovarian pure clear cell carcinoma.

METHODS: This was a retrospective study involving data from 11 ultrasound centers. From the International Ovarian Tumor Analysis (IOTA) database, 105 patients who had undergone preoperative ultrasound examination by an experienced ultrasound examiner between 1999 and 2016 were identified with a histologically confirmed pure clear cell carcinoma of the ovary. An additional 47 patients diagnosed with pure clear cell carcinoma between 1999 and 2016 and with available complete preoperative ultrasound reports were identified retrospectively from the databases of the departments of gynecological oncology in the participating centers. The ultrasound images of all tumors were described using IOTA terminology. Clinical and ultrasound characteristics were analyzed for the whole group, and separately, for patients with and those without histologically confirmed endometriosis, and for patients with evidence of tumor developing from endometriosis.

RESULTS: Median age of the 152 patients was 53.5 (range, 28-92) years and 92/152 (60.5%) tumors were FIGO Stage I. Most tumors (128/152, 84.2%) were unilateral. On ultrasound examination, all tumors contained solid components and 36/152 (23.7%) were completely solid masses. The median largest diameter of the lesion was 117 (range, 25-310) mm. Papillary projections were present in 58/152 (38.2%) masses and, in most of these (51/56, 91.1%), vascularized papillary projections were seen. Information regarding the presence, site and type of pelvic endometriosis at histology was available for 130/152 patients. Endometriosis was noted in 54 (41.5%) of these. In 24/130 (18.6%) patients, the tumor was judged to have developed from endometriosis. Patients with, compared to those without, evidence of tumor developing from endometriosis were younger (median 47.5 vs 55.0 years, respectively), and ground-glass echogenicity of cyst fluid was more common in pure clear cell cancers developing from endometriosis (10/20 vs 13/79 (50.0% vs 16.5%), respectively).

CONCLUSIONS: Ovarian pure clear cell carcinoma is usually diagnosed at an early stage and typically appears as a large unilateral mass with solid components. Patients with clear cell carcinoma developing from endometriosis are younger than other patients with clear cell carcinoma, and clear cell cancers developing from endometriosis more often manifest ground-glass echogenicity of cyst fluid. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pozzati F, Moro F, Pasciuto T, et al. Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma. Ultrasound Obstet Gynecol. 2018. PMID: 29978567. doi:10.1002/uog.19171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。